自身免疫性甲状腺病患者血清可溶TACI水平与甲状腺功能和抗体的相关性研究

Serum soluble TACI level in patients with autoimmune thyroid diseases and its correlation with thyroid function and autoimmune antibodies

目的:TACI是BAFF/APRIL通路系统的重要受体。本研究通过检测不同类型自身免疫性甲状腺病(autoimmune thyroid diseases,AITD)患者的血清可溶TACI(soluble TACI,sTACI)水平,分析sTACI与甲状腺功能和抗体的相关性,探讨sTACI在AITD发生中的作用。方法:招募中国医科大学附属第一医院门诊就诊的新诊断格雷夫斯病(Graves disease,GD)和桥本甲状腺炎(Hashimoto thyroiditis,HT)患者,以及体检中心的健康体检者。采集静脉血,分离血清,电化学免疫发光法测定甲状腺功能和甲状腺抗体水平,酶联免疫吸附法测定血清sTACI表达水平。结果:GD组和HT组研究对象的年龄、性别与正常对照(normal control,NC)组相比,均无统计学差异(均P>0.05)。GD组、HT组和NC组患者的血清sTACI水平分别为13.24(10.40~18.60)pg/mL、12.75(11.17~16.14)pg/mL和13.05(10.30~18.75)pg/mL。与NC组相比,GD组和HT组患者的血清sTACI水平无统计学差异(P=0.812,P=0.873);GD和HT两组患者相比,血清sTACI的表达水平亦无统计学差异(P=0.584)。GD组患者的血清sTACI水平与血清游离甲状腺素(free thyroxine,FT4)、游离三碘甲状腺原氨酸(free triiodothyronine,FT3)、促甲状腺激素(thyroid stimulating hormone,TSH)、甲状腺过氧化物酶抗体(thyroid peroxidase antibody,TPOAb)、甲状腺球蛋白抗体(thyroglobulin antibody,TgAb)和促甲状腺素受体抗体(thyrotropin receptor antibody,TRAb)水平均无显著相关性(均P>0.05);HT组患者的血清sTACI水平与FT4、FT3、TSH、TPOAb和TgAb水平亦无相关(均P>0.05)。结论:与NC组相比,AITD患者的血清sTACI水平无明显变化,且与甲状腺功能和抗体指标均无相关性,提示BAFF/APRIL通路系统中的TACI受体并非AITD发生发展的关键因子。

Objective:TACI is an important receptor of BAFF/APRIL pathway system.To investigate the level of serum soluble TACI(sTACI)in patients with different types of autoimmune thyroid diseases(AITD),to analyze its relationship with thyroid function and autoimmune antibody,and to explore the role of sTACI in AITD.Methods:Patients who were newly diagnosed with Graves disease(GD)and Hashimoto thyroiditis(HT)in our department and healthy people who had physical examination in physical examination center of our hospital were recruited.Venous blood samples were collected and serum was separated.Expression levels of thyroid function and autoimmune antibody were measured by electrochemical immunoluminescence and expression levels of serum sTACI were measured by enzyme linked immunosorbent assay(ELISA).Results:Age and gender in the GD group and the HT group had no statistical difference when compared with that in the normal control(NC)group(both P>0.05).The level of serum sTACI in the GD group,the HT group and the NC group were 13.24(10.40-18.60)pg/mL,12.75(11.17-16.14)pg/mL and 13.05(10.30-18.75)pg/mL,respectively.The level of serum sTACI in the GD group and the HT group had no significant difference when compared with that in the NC group(P=0.812,0.873).The level of serum sTACI had no statistical difference between the GD group and the HT group(P=0.584).In the GD group,the level of serum sTACI was not correlated with FT4,FT3,TSH,TPOAb,TgAb and TRAb level(all P>0.05).In the HT group,the level of serum sTACI was not correlated with FT4,FT3,TSH,TPOAb and TgAb level(all P>0.05).Conclusion:Compared with the NC group,the level of serum sTACI in AITD patients has no significant change and it has no correlation with thyroid function and autoimmune antibody level,suggesting that TACI receptor of BAFF/APRIL pathway system may not play a crucial role in the pathogenesis of AITD.